Bailey Fisher’s Private Markets Dinner is a peer-to-peer forum for owner managed, privately owned, private equity backed and listed company leaders to meet for dinner and discussion on issues of relevance to their role. Dinners are hosted by Andrew Moore, Partner and Head of the Private Markets Practice.
We are delighted to welcome as our guest speaker, Barry Chevallier Guild – Aspall Cyder. A proud custodian of Aspall’s rich 290 year heritage, Barry will share insight into taking his family business through a trade sale, following the acquisition of Aspall by Molson Coors earlier this year.
The dinner is hosted by Bailey Fisher in partnership with Farrer & Co and PwC UK.
Matthew is commercial and technology lead for cross sector AI and Cognitive projects at Deloitte, spanning strategy, prototyping & proof of concept/value, implementation and integration. He was previously European Lead for IBM Watson Health.
Expert at scaling companies at the intersection of life science and data science. He has built and exited a number of IP rich B2B software companies. He was responsible for the turnaround and sale of Psytechnics to US Nasdaq listed NetScout; and as MD of MetaSolv, doubled the size of the European business prior to acquisition by Oracle.
Postdoctoral Research Associate on the AI Narratives project, exploring the public understanding of AI as constructed by fictional and nonfictional narratives. Kanta’s cutting edge research intersects the fields of science communication, literature and science, and science fiction.
World-renowned expert in the use of AI within education, focusing on showing teachers and students the detail of their progress intellectually, emotionally and socially. The lead author of Nesta’s influential ‘Decoding Learning’ report and Pearson’s ‘Unleashing Intelligence’, Rose also informed the Government’s AI strategy, published in 2017.
Ian has 25+ years’ experience in life sciences, from academic research to biotech start-up to big pharma. He founded Domantis with Sir Gregory Winter, acquired by GSK for $454m and was SVP, Head of Worldwide Business Development & Head of Biopharm R&D at GSK. Currently Chairman of Stevenage Bioscience Catalyst, the UK’s first open innovation biomedical campus; chair of the Investment Committee for Apollo Therapeutics, a £40m fund dedicated to turning academic biotechnologies into novel medicines.
Shirin has led winning teams within start-up, SME and larger corporates. As Founder/CEO of Arieso, she led a decade of remarkable company growth, culminating in an exit to JDSU in 2013. Shirin is now Chairwoman of Opensignal, and a Senior Partner at Frog Capital, the London based European VC focused on scale up stage companies.
March 2018: International Women’s Day Dinner in Cambridge with guest speaker Pam Garside, Cambridge Angel; Founder – Newhealth; Fellow – Judge Business School. Discussion moderated by Simon Calver, BGF Ventures.
Jenny has over 20 years’ experience facilitating SME access to investment in the UK & internationally. At UKBAA she focuses on building the angel community around the UK, connecting investors to good deal flow and assisting entrepreneurs to attract investors. Jenny was awarded an OBE in 2015 for services to small businesses.